BC
TVTX icon

Bridgefront Capital’s Travere Therapeutics TVTX Stock Holding History

Bridgefront Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,168
Closed -$182K – 857
2025
Q1 		$182K Buy
+10,168
New +$206K 0.05% 534
2024
Q4 		– Sell
-17,688
Closed -$247K – 788
2024
Q3 		$247K Buy
17,688
+7,623
+76% +$79.4K 0.1% 390
2024
Q2 		$82.7K Buy
+10,065
New +$67.8K 0.03% 454
2024
Q1 		– Sell
-10,329
Closed -$92.9K – 558
2023
Q4 		$92.9K Buy
+10,329
New +$75.2K 0.07% 341

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgefront Capital's TVTX Position: Q2 2025 in Review

Bridgefront Capital sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 10,168 shares — an estimated $182K sold.

Bridgefront Capital first reported a position in TVTX in Q4 2023 and held it in 4 quarters. The position peaked at $247K in Q3 2024. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • Bridgefront Capital reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bridgefront Capital sold 10,168 Travere Therapeutics shares in Q2 2025, an estimated $182K.
  • Bridgefront Capital first reported a position in Travere Therapeutics in Q4 2023 and held it in 4 quarters.
  • Bridgefront Capital's Travere Therapeutics position peaked at $247K in Q3 2024.
  • 211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.